A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
[P1]	 O
Temsirolimus	 O
[P2]	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
LotharBergmann	 O

A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
[P1]	 O
Sunitinib	 O
[P2]	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
LotharBergmann	 O

A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
[P1]	 O
Temsirolimus	 O
[P2]	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
LotharBergmann	 O

A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
[P1]	 O
Sunitinib	 O
[P2]	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
LotharBergmann	 O

A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
[P1]	 O
Temsirolimus	 O
[P2]	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O

A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
[P1]	 O
Sunitinib	 O
[P2]	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O

A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
[P1]	 O
Temsirolimus	 O
[P2]	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
LotharBergmann	 O
l.bergmann@em.uni-frankfurt.de	 O
Medical	 O
Clinic	 O
II	 O
J.W.	 O
Goethe	 O
University	 O
Frankfurt	 O

A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
[P1]	 O
Sunitinib	 O
[P2]	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
LotharBergmann	 O
l.bergmann@em.uni-frankfurt.de	 O
Medical	 O
Clinic	 O
II	 O
J.W.	 O
Goethe	 O
University	 O
Frankfurt	 O

Germany	 O
Theodor	 O
-	 O
Stern	 O
-	 O
Kai	 O
7	 O
DE	 O
60590	 O
Frankfurt	 O
Germany	 O
A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
[P1]	 O
Temsirolimus	 O
[P2]	 O
versus	 O
Sunitinib	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
10.1159/000508450	 O
Received	 O
:	 O
February	 O
27	 O
,	 O
2020	 O
Accepted	 O
:	 O
May	 O
6	 O
,	 O
2020	 O

Germany	 O
Theodor	 O
-	 O
Stern	 O
-	 O
Kai	 O
7	 O
DE	 O
60590	 O
Frankfurt	 O
Germany	 O
A	 O
Randomized	 O
Phase	 O
IIa	 O
Trial	 O
with	 O
Temsirolimus	 O
versus	 O
[P1]	 O
Sunitinib	 O
[P2]	 O
in	 O
Advanced	 O
Non	 O
-	 O
Clear	 O
Cell	 O
Renal	 O
Cell	 O
Carcinoma	 O
:	 O
An	 O
Intergroup	 O
Study	 O
of	 O
the	 O
CESAR	 O
Central	 O
European	 O
Society	 O
for	 O
Anticancer	 O
Drug	 O
Research	 O
-	 O
EWIV	 O
and	 O
the	 O
Interdisciplinary	 O
Working	 O
Group	 O
on	 O
Renal	 O
Cell	 O
Cancer	 O
(	 O
IAGN	 O
)	 O
of	 O
the	 O
German	 O
Cancer	 O
Society	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
June	 O
15	 O
,	 O
2020	 O
10.1159/000508450	 O
Received	 O
:	 O
February	 O
27	 O
,	 O
2020	 O
Accepted	 O
:	 O
May	 O
6	 O
,	 O
2020	 O

Furthermore	 O
,	 O
new	 O
entities	 O
of	 O
nccRCC	 O
were	 O
described	 O
in	 O
the	 O
2016	 O
WHO	 O
classification	 O
[	 O
15	 O
]	 O
In	 O
this	 O
small	 O
multicenter	 O
prospectively	 O
randomized	 O
phase	 O
IIa	 O
trial	 O
,	 O
[P1]	 O
TEM	 O
[P2]	 O
was	 O
compared	 O
to	 O
SUN	 O
in	 O
nccRCC	 O
.	 O

Furthermore	 O
,	 O
new	 O
entities	 O
of	 O
nccRCC	 O
were	 O
described	 O
in	 O
the	 O
2016	 O
WHO	 O
classification	 O
[	 O
15	 O
]	 O
In	 O
this	 O
small	 O
multicenter	 O
prospectively	 O
randomized	 O
phase	 O
IIa	 O
trial	 O
,	 O
TEM	 O
was	 O
compared	 O
to	 O
[P1]	 O
SUN	 O
[P2]	 O
in	 O
nccRCC	 O
.	 O

Patients	 O
who	 O
met	 O
the	 O
eligibility	 O
criteria	 O
were	 O
randomly	 O
assigned	 O
1	 O
:	 O
1	 O
to	 O
receive	 O
either	 O
[P1]	 O
SUN	 O
[P2]	 O
50	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
day	 I-DOSAGE
p.o	 I-DOSAGE
.	 I-DOSAGE

for	 I-DOSAGE
4	 I-DOSAGE
weeks	 I-DOSAGE
,	 I-DOSAGE
followed	 I-DOSAGE
by	 I-DOSAGE
2	 I-DOSAGE
weeks	 I-DOSAGE
rest	 I-DOSAGE
each	 I-DOSAGE
or	 O
25	 B-DOSAGE
mg	 I-DOSAGE
[P1]	 O
TEM	 O
[P2]	 O
as	 B-DOSAGE
weekly	 I-DOSAGE
infusions	 I-DOSAGE
.	 O

Twelve	 O
patients	 O
were	 O
randomized	 O
to	 O
[P1]	 O
arm	 O
A	 O
(	 O
TEM	 O
)	 O
[P2]	 O
and	 O
10	 O
patients	 O
to	 O
arm	 O
B	 O
(	 O
SUN	 O
)	 O
.	 O

Twelve	 O
patients	 O
were	 O
randomized	 O
to	 O
arm	 O
A	 O
(	 O
TEM	 O
)	 O
and	 O
10	 O
patients	 O
to	 O
[P1]	 O
arm	 O
B	 O
(	 O
SUN	 O
)	 O
[P2]	 O
.	 O

The	 O
median	 O
treatment	 O
duration	 O
was	 O
slightly	 O
but	 O
not	 O
significantly	 O
lower	 O
in	 O
the	 O
[P1]	 O
TEM	 O
group	 O
[P2]	 O
.	 O

In	 O
the	 O
[P1]	 O
TEM	 O
arm	 O
[P2]	 O
,	 O
2	 O
of	 O
12	 O
patients	 O
achieved	 O
a	 O
partial	 O
remission	 O
(	 O
PR	 O
)	 O
and	 O
5	 O
of	 O
12	 O
patients	 O
a	 O
stable	 O
disease	 O
(	 O
SD	 O
)	 O
compared	 O
to	 O
3	 O
of	 O
10	 O
and	 O
6	 O
of	 O
10	 O
patients	 O
in	 O
the	 O
SUN	 O
arm	 O
,	 O
respectively	 O
(	 O
Table	 O
2	 O
)	 O
.	 O

In	 O
the	 O
TEM	 O
arm	 O
,	 O
2	 O
of	 O
12	 O
patients	 O
achieved	 O
a	 O
partial	 O
remission	 O
(	 O
PR	 O
)	 O
and	 O
5	 O
of	 O
12	 O
patients	 O
a	 O
stable	 O
disease	 O
(	 O
SD	 O
)	 O
compared	 O
to	 O
3	 O
of	 O
10	 O
and	 O
6	 O
of	 O
10	 O
patients	 O
in	 O
the	 O
[P1]	 O
SUN	 O
arm	 O
[P2]	 O
,	 O
respectively	 O
(	 O
Table	 O
2	 O
)	 O
.	 O

The	 O
tumor	 O
control	 O
rate	 O
(	 O
CR	 O
+	 O
PR	 O
+	 O
SD	 O
)	 O
was	 O
77.8	 O
%	 O
in	 O
the	 O
GEM	 O
arm	 O
and	 O
90	 O
%	 O
in	 O
the	 O
[P1]	 O
SUN	 O
arm	 O
[P2]	 O
.	 O

The	 O
median	 B-METRIC
PFS	 I-METRIC
for	 O
[P1]	 O
TEM	 O
[P2]	 O
was	 O
inferior	 O
with	 O
9.3	 B-RESULTS
versus	 O
13.2	 B-RESULTS
months	 I-RESULTS
for	 O
SUN	 O
,	 O
but	 O
the	 O
difference	 O
was	 O
statistically	 O
not	 O
significant	 O
and	 O
the	 O
primary	 O
endpoint	 O
was	 O
not	 O
Oncol	 O
Res	 O
Treat	 O
2020;43:333	 O
-	 O
338	 O
DOI	 O
:	 O
10.1159/000508450	 O
met	 O
(	 O
Fig	 O
.	 O

The	 O
median	 B-METRIC
PFS	 I-METRIC
for	 O
TEM	 O
was	 O
inferior	 O
with	 O
9.3	 B-RESULTS
versus	 O
13.2	 B-RESULTS
months	 I-RESULTS
for	 O
[P1]	 O
SUN	 O
[P2]	 O
,	 O
but	 O
the	 O
difference	 O
was	 O
statistically	 O
not	 O
significant	 O
and	 O
the	 O
primary	 O
endpoint	 O
was	 O
not	 O
Oncol	 O
Res	 O
Treat	 O
2020;43:333	 O
-	 O
338	 O
DOI	 O
:	 O
10.1159/000508450	 O
met	 O
(	 O
Fig	 O
.	 O

There	 O
was	 O
no	 O
difference	 O
in	 O
mOS	 O
with	 O
19.4	 O
months	 O
[P1]	 O
TEM	 O
[P2]	 O
and	 O
19.8	 O
months	 O
for	 O
SUN	 O
(	 O
Fig	 O
.	 O

There	 O
was	 O
no	 O
difference	 O
in	 O
mOS	 O
with	 O
19.4	 O
months	 O
TEM	 O
and	 O
19.8	 O
months	 O
for	 O
[P1]	 O
SUN	 O
[P2]	 O
(	 O
Fig	 O
.	 O

No	 O
dose	 O
modifications	 O
have	 O
been	 O
reported	 O
in	 O
the	 O
[P1]	 O
TEM	 O
arm	 O
[P2]	 O
,	 O
but	 O
7	 O
of	 O
10	 O
patients	 O
experienced	 O
at	 O
least	 O
one	 O
dose	 O
modification	 O
(	 O
reduction	 O
)	 O
during	 O
the	 O
treatment	 O
period	 O
in	 O
the	 O
SUN	 O
arm	 O
.	 O

No	 O
dose	 O
modifications	 O
have	 O
been	 O
reported	 O
in	 O
the	 O
TEM	 O
arm	 O
,	 O
but	 O
7	 O
of	 O
10	 O
patients	 O
experienced	 O
at	 O
least	 O
one	 O
dose	 O
modification	 O
(	 O
reduction	 O
)	 O
during	 O
the	 O
treatment	 O
period	 O
in	 O
the	 O
[P1]	 O
SUN	 O
arm	 O
[P2]	 O
.	 O

Eleven	 O
of	 O
12	 O
patients	 O
had	 O
drug	 O
-	 O
related	 O
severe	 O
adverse	 O
events	 O
(	 O
SAE	 O
)	 O
in	 O
the	 O
[P1]	 O
TEM	 O
arm	 O
[P2]	 O
and	 O
all	 O
patients	 O
in	 O
the	 O
SUN	 O
arm	 O
(	 O
Table	 O
3	 O
)	 O
.	 O

Eleven	 O
of	 O
12	 O
patients	 O
had	 O
drug	 O
-	 O
related	 O
severe	 O
adverse	 O
events	 O
(	 O
SAE	 O
)	 O
in	 O
the	 O
TEM	 O
arm	 O
and	 O
all	 O
patients	 O
in	 O
the	 O
[P1]	 O
SUN	 O
arm	 O
[P2]	 O
(	 O
Table	 O
3	 O
)	 O
.	 O